Celvestrant PFS Injection 250 mg
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Celvestrant PFS Injection 250 mg contains fulvestrant, an estrogen receptor antagonist (estrogen blocker) supplied in a pre-filled syringe (PFS). Its labelling describes it for the treatment of breast cancer in women who have gone through menopause. Breast cancer cells need estrogen to grow; fulvestrant is described as inhibiting the action of estrogen on breast cancer cells, which helps lower or stop the growth of some cancerous cells.
Product Information
The following description reflects information associated with this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the treatment of breast cancer in women who have gone through menopause
- Described as adjusting the level of estrogen to slow the growth of cancer cells
- Described as inhibiting the action of estrogen on breast cancer cells to lower or stop the growth of some cancerous cells
Described Dosage & Administration
- Taken only if prescribed by the doctor; it should not be self-administered
- Administered by a healthcare provider or doctor as per the dosage needed, depending on the patient’s condition
Described Side Effects
Commonly described side effects include:
- Nausea and vomiting
- Weakness and fatigue
- Back pain
- Injection site pain
- Decreased appetite
- Joint pain and musculoskeletal pain
- Constipation
- Cough
These are described as commonly temporary. Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- Taken only after consulting the doctor
- The doctor should be informed of any kidney or liver-related problems before use
- Pregnant women should consult a doctor before use; described as unsafe for breastfeeding mothers, as it may cause toxicity to the baby
- A proper diet should be followed and alcohol avoided during treatment
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical and healthcare products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains fulvestrant and is used for the treatment of breast cancer in postmenopausal women. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling describes it as administered by a healthcare provider or doctor, only if prescribed, as per the dosage needed depending on the patient’s condition.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.